Bowen Acquisition Corp
BOWNR
NASDAQ Global Market0.23
USD
+0.00
- -
CIK
0001973056
ISIN
KYG127291287
Return %
Stock
S&P500
1Y
1.81
18.21
3Y
18.53
64.38
5Y
18.53
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jiangang Luo
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 420 Lexington Avenue New York City NY United States of America 10170
- IPO Date
- Aug 17, 2023
- CIK
- 0001973056
- Website
- bowenspac.com
- Similar Companies
- Business
- Bowen Acquisition Corp (NASDAQ: BOWN; BOWNR) is a blank check company, or special purpose acquisition company (SPAC), incorporated in the Cayman Islands and headquartered in New York, New York; the firm was formed in 2023 to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. Bowen Acquisition Corp focuses primarily on identifying attractive targets in Asia, excluding any entities with China operations consolidated through a variable interest entity (VIE) structure; its core activities encompass raising capital via an initial public offering, which raised $60 million in July 2023 plus a full over-allotment option, and holding proceeds in trust pending a qualifying transaction, with redeemable warrants traded under the BOWNR ticker; the company offers public shareholders redemption rights and targets sectors without geographic or industry limitations beyond its initial Asia emphasis. Geographically, Bowen Acquisition Corp operates from the United States while pursuing opportunities across Asia; its management team provides expertise in financial services, accounting, legal matters, mergers and acquisitions, and operations in multiple jurisdictions. In recent developments, Bowen Acquisition Corp announced a definitive merger agreement on January 19, 2024, with Shenzhen Qianzhi BioTech Company Ltd., a China-based health and wellness biotechnology firm specializing in ozonated, plant-based products for antibacterial, skincare, gynecological, and andrological applications, as well as proprietary ozonated disinfectants; the transaction values the pro forma entity at approximately $96.9 million enterprise value ($167 million equity value assuming no redemptions and a $5 million PIPE raise), with Qianzhi BioTech shareholders receiving 7,246,377 ordinary shares and up to 1.4 million earnout shares tied to net income milestones for fiscal years ending March 31, 2025, and 2026; the deal, originally targeted for Q2 or Q3 2024 closure, includes efforts to secure $5 million in PIPE financing, no minimum cash condition, and approvals from CFIUS and CSRC, though it faces ongoing delays evidenced by shareholder votes to extend deadlines including an extraordinary general meeting on July 11, 2025, and an amendment vote scheduled for December 12, 2025. Amid merger pursuit, Bowen Acquisition Corp received a Nasdaq delisting determination on July 15, 2025, for multiple compliance issues including insufficient market value, prompting an appeal by July 22, 2025, to avert trading suspension on July 24, 2025, with the company asserting the Qianzhi BioTech combination will restore compliance if consummated.